(Reuters) - An experimental treatment for type 2 diabetes developed by Johnson & Johnson demonstrated greater reduction in blood sugar than Merck & Co's Januvia and an older common treatment, ...
Merck announced that expanded labeling has been approved for Januvia (sitagliptin), the only DPP-4 inhibitor indicated domestically as an adjunct to diet and exercise to improve glycemic control in ...
June 9 (Reuters) - An experimental treatment for type 2 diabetes developed by Johnson & Johnson demonstrated greater reduction in blood sugar than Merck & Co's Januvia and an older common treatment, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback